We are monitoring the impact of COVID-19 on APAC Monoclonal Antibodies Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1122
Share on
Share on

APAC Monoclonal Antibodies Market Research Report – Segmented By Source, Indication, End-User, Application, Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: February, 2020
ID: 1122
Pages: 137

APAC Monoclonal Antibodies Market Size (2021 to 2026)

The size of the Monoclonal Antibodies Market in the Asia Pacific is estimated to value USD 7.74 Billion by 2026 from USD 6.21 Billion in 2021, growing at a compound annual growth rate (CAGR) of 4.52% between 2021 to 2026.

The APAC monoclonal antibodies market is expected to be driven by the factors such as the increasing incidence of cancer and other chronic diseases across APAC, creating the demand for biologics. Monoclonal antibodies have the ability to recognize and destroy unhealthy cells immediately, suppress cancer cell proliferation, and distribute radioactive particles or chemotherapy medications to individual cells, reducing the risk of medication-related side effects while also improving immune system activity. In addition, increasing research and development activities in genomics along with the adoption of technology in emerging countries such as China and India are propelling the monoclonal antibodies market over the forecast period. More firms in the region will likely try to enter the market due to the possibility of strong future growth.

Some other promising factors driving the market include increased awareness of mAb therapy applications among patients and physicians, introducing better products regularly, the growing adoption of therapeutic antibodies in cost-sensitive markets, and regulatory approval of breakthrough therapies by regulatory authorities. The need for APAC monoclonal antibodies is expanding as more cost-effective biosimilar monoclonal antibodies become available. The increased prevalence of cancer is expected to increase the demand for infusion treatments. Antibody vaccines are more effective at inducing the desired medication, which results in the production of monoclonal antibodies (mAbs), which invade a specific region or cell. The technology's low cost makes it a good fit for conducting research studies to create mAbs. Moreover, the market in the region is expected to expand due to a growing number of government programs and support for clinical trials of medicines used in the Covid-19 treatment.

Strict standards governing the production of mAbs, on the other hand, may act as a barrier. Alternative therapeutic alternatives are growing increasingly popular throughout the world, which is projected to impact the market for monoclonal antibody drugs. Furthermore, alternative therapies such as Homeopathy, Ayurveda, yoga, acupuncture, and sujok therapy favor and eventually replace certain traditional hospital operations, which is likely to limit the market.

This research report on the APAC monoclonal antibodies market has been segmented & sub-segmented into the following categories:

By Source:

  • Murine
  • Chimeric
  • Humanized
  • Human

By Indication:

  • Cancer
    • Blood Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Pancreatic Cancer
    • Others
  • Autoimmune Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • CNS Disorders
  • Others (Inflammatory, Microbial Diseases, & Other)

By End-User:

  • Hospitals/Clinics
  • Research Institute
  • Diagnostic Laboratories

By Application:

  • Medical
  • Experimental
  • Western Blot
    • ELISA
    • Radioimmune Assays
    • Immunofluorescence
    • Others

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Regional Analysis:

The APAC monoclonal antibodies market had accounted for a significant share in the global market in 2020 and is driven by the increased potential market players, increasing disposable income, and rising awareness about the therapeutic use of mAbs. Also, the proliferation of cost-efficient biosimilar monoclonal antibodies is further expected to drive the market in this region. The region has seen an increase in the number of approvals for monoclonal antibodies biosimilars, owing to the government's increased focus on enhancing patient access to treatment. Biocon Ltd., Amgen Inc., F. Hoffman La-Roche AG, Pfizer Inc., and Mylan N.V. are some of the market's major participants. Product launches, partnerships, and collaborations are considered to be some of the probable methods used by market participants to improve their market position. Market players in the region are China, Japan, and India, majorly contributing to regional market growth. The Indian monoclonal Antibodies Market is projected to witness the highest market share in the region over the forecast period owing to the fundamental change in the pharmaceutical and biotechnology sectors and support from the government. 

KEY MARKET PLAYERS:

Some of the leading companies in the APAC Monoclonal Antibodies Market profiled in this report are GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Seattle Genetics, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd. and Biogen Inc.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods 

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Source                    

                                5.1.1 Murine     

                                5.1.2 Chimeric  

                                5.1.3 Humanized             

                                5.1.4 Human     

                5.2 By Indication                              

                                5.2.1 Cancer      

                                                5.2.1.1 Blood Cancer

                                                5.2.1.2 Breast Cancer

                                                5.2.1.3 Colorectal Cancer

                                                5.2.1.4 Lung Cancer

                                                5.2.1.5 Pancreatic Cancer

                                                5.2.1.6 Others

                                5.2.2 Autoimmune Diseases       

                                5.2.3 Infectious Diseases             

                                5.2.4 Cardiovascular Diseases    

                                5.2.5 CNS Disorders       

                                5.2.6 Others (Inflammatory, Microbial Diseases, & Other)             

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

                5.4 Application                 

                                5.4.1 Medical    

                                5.4.2 Experimental         

                                                5.4.2.1 Western Blot

                                                5.4.2.2 ELISA

                                                5.4.2.3 Radioimmune Assays 

                                                5.4.2.4 Immunofluorescence 

                                                5.4.2.5 Other (Immunohistochemistry, Immunoprecipitation, & Immunocytochemistry)

6. Geographical Analysis                                              

                6.1 Asia-Pacific                 

                                6.1.1 Introduction           

                                6.1.2 China         

                                6.1.3 India          

                                6.1.4 Japan        

                                6.1.5 South Korea           

                                6.1.6 Australia  

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Monoclonal Antibodies Development                 

                                7.5.1 Targeted Therapies             

                7.6 Promising Monoclonal Antibodies in Pipeline                              

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies                   

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 GlaxoSmithKline plc (U.K.)                   

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Novartis AG (Switzerland)                    

                9.3 Pfizer Inc. (U.S.)                       

                9.4 Thermo Fisher Scientific Inc. (U.S.)                   

                9.5 Eli Lilly and Company (U.S.)                 

                9.6 Innovent Biologics (China)                   

                9.7 Bristol-Myers Squibb (U.S.)                 

                9.8 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.9 Shanghai Junshi Bioscience Co.,Ltd. (China)                  

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Market Outlook & Investment Opportunities                               

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Monoclonal Antibodies Market By Murine, From 2021 to 2026 ( USD Billion )
  2. Asia-Pacific Chimeric Market By Region, From 2021 to 2026 ( USD Billion )
  3. Asia-Pacific Humanized Market By Region, From 2021 to 2026 ( USD Billion )
  4. Asia-Pacific Human Market By Region, From 2021 to 2026 ( USD Billion )
  5. Asia-Pacific Monoclonal Antibodies Market By Cancer, From 2021 to 2026 ( USD Billion )
  6. Asia-Pacific Autoimmune Diseases Market By Region, From 2021 to 2026 ( USD Billion )
  7. Asia-Pacific Infectious Diseases Market By Region, From 2021 to 2026 ( USD Billion )
  8. Asia-Pacific Cardiovascular Diseases Market By Region, From 2021 to 2026 ( USD Billion )
  9. Asia-Pacific CNS Disorders Market By Region, From 2021 to 2026 ( USD Billion )
  10. Asia-Pacific Others (Inflammatory, Microbial Diseases, & Other) Market By Region, From 2021 to 2026 ( USD Billion )
  11. Asia-Pacific Monoclonal Antibodies Market By Hospitals/Clinics, From 2021 to 2026 ( USD Billion )
  12. Asia-Pacific Research Institute Market By Region, From 2021 to 2026 ( USD Billion )
  13. Asia-Pacific Diagnostic Laboratories Market By Region, From 2021 to 2026 ( USD Billion )
  14. Asia-Pacific Monoclonal Antibodies Market By Medical, From 2021 to 2026 ( USD Billion )
  15. Asia-Pacific Experimental Market By Region, From 2021 to 2026 ( USD Billion )
  16. Japan Monoclonal Antibodies Market By Murine, From 2021 to 2026 ( USD Billion )
  17. Japan Monoclonal Antibodies Market By Cancer, From 2021 to 2026 ( USD Billion )
  18. Japan Monoclonal Antibodies Market By Hospitals/Clinics, From 2021 to 2026 ( USD Billion )
  19. Japan Monoclonal Antibodies Market By Medical, From 2021 to 2026 ( USD Billion )
  20. China Monoclonal Antibodies Market By Murine, From 2021 to 2026 ( USD Billion )
  21. China Monoclonal Antibodies Market By Cancer, From 2021 to 2026 ( USD Billion )
  22. China Monoclonal Antibodies Market By Hospitals/Clinics, From 2021 to 2026 ( USD Billion )
  23. China Monoclonal Antibodies Market By Medical, From 2021 to 2026 ( USD Billion )
  24. India Monoclonal Antibodies Market By Murine, From 2021 to 2026 ( USD Billion )
  25. India Monoclonal Antibodies Market By Cancer, From 2021 to 2026 ( USD Billion )
  26. India Monoclonal Antibodies Market By Hospitals/Clinics, From 2021 to 2026 ( USD Billion )
  27. India Monoclonal Antibodies Market By Medical, From 2021 to 2026 ( USD Billion )
  28. South Korea Monoclonal Antibodies Market By Murine, From 2021 to 2026 ( USD Billion )
  29. South Korea Monoclonal Antibodies Market By Cancer, From 2021 to 2026 ( USD Billion )
  30. South Korea Monoclonal Antibodies Market By Hospitals/Clinics, From 2021 to 2026 ( USD Billion )
  31. South Korea Monoclonal Antibodies Market By Medical, From 2021 to 2026 ( USD Billion )
  32. Australia Monoclonal Antibodies Market By Murine, From 2021 to 2026 ( USD Billion )
  33. Australia Monoclonal Antibodies Market By Cancer, From 2021 to 2026 ( USD Billion )
  34. Australia Monoclonal Antibodies Market By Hospitals/Clinics, From 2021 to 2026 ( USD Billion )
  35. Australia Monoclonal Antibodies Market By Medical, From 2021 to 2026 ( USD Billion )
  36. Asia-Pacific Monoclonal Antibodies Market By Blood Cancer, From 2021 to 2026 ( USD Billion )
  37. Asia-Pacific Breast Cancer Market By Region, From 2021 to 2026 ( USD Billion )
  38. Asia-Pacific Colorectal Cancer Market By Region, From 2021 to 2026 ( USD Billion )
  39. Asia-Pacific Lung Cancer Market By Region, From 2021 to 2026 ( USD Billion )
  40. Asia-Pacific Pancreatic Cancer Market By Region, From 2021 to 2026 ( USD Billion )
  41. Asia-Pacific Others Market By Region, From 2021 to 2026 ( USD Billion )
  42. Japan Monoclonal Antibodies Market By Blood Cancer, From 2021 to 2026 ( USD Billion )
  43. China Monoclonal Antibodies Market By Blood Cancer, From 2021 to 2026 ( USD Billion )
  44. India Monoclonal Antibodies Market By Blood Cancer, From 2021 to 2026 ( USD Billion )
  45. Souh Korea Monoclonal Antibodies Market By Blood Cancer, From 2021 to 2026 ( USD Billion )
  46. Asia-Pacific Monoclonal Antibodies Market By Western Blot, From 2021 to 2026 ( USD Billion )
  47. Asia-Pacific ELISA Market By Region, From 2021 to 2026 ( USD Billion )
  48. Asia-Pacific Radioimmune Assays Market By Region, From 2021 to 2026 ( USD Billion )
  49. Asia-Pacific Immunofluorescence Market By Region, From 2021 to 2026 ( USD Billion )
  50. Asia-Pacific Others Market By Region, From 2021 to 2026 ( USD Billion )
  51. Japan Monoclonal Antibodies Market By Western Blot, From 2021 to 2026 ( USD Billion )
  52. China Monoclonal Antibodies Market By Western Blot, From 2021 to 2026 ( USD Billion )
  53. India Monoclonal Antibodies Market By Western Blot, From 2021 to 2026 ( USD Billion )
  54. Souh Korea Monoclonal Antibodies Market By Western Blot, From 2021 to 2026 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample